82935-42-0 Usage
Description
Remoxipride, also known as Remoxipride hydrochloride, is a selective dopamine D2-antagonist primarily used for the treatment of schizophrenia and other psychoses where thought disorders are prominent symptoms. It is known for its efficacy similar to haloperidol but with significantly fewer extrapyramidal side-effects. Remoxipride is marketed under the brand name Roxiam.
Uses
Used in Pharmaceutical Industry:
Remoxipride is used as an antipsychotic medication for the treatment of schizophrenia and other psychoses. It works by selectively blocking dopamine D2 receptors in the brain, which helps alleviate thought disorders and other psychotic symptoms.
Used in Neurology:
Remoxipride is used as a neuroleptic agent to manage the symptoms of schizophrenia and other related psychoses. Its selective action on dopamine D2 receptors allows for effective symptom control with a lower risk of extrapyramidal side-effects compared to some other antipsychotic medications.
Check Digit Verification of cas no
The CAS Registry Mumber 82935-42-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,2,9,3 and 5 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 82935-42:
(7*8)+(6*2)+(5*9)+(4*3)+(3*5)+(2*4)+(1*2)=150
150 % 10 = 0
So 82935-42-0 is a valid CAS Registry Number.
82935-42-0Relevant articles and documents
3-Aminomethylbiphenyls. A New Class of Dopamine Receptor Ligands
Thurkauf, Andrew,Yuan, Jun,Chen, Xi,Wasley, Jan W. F.,Paneitz, Gregory,Meade, Robin,Woodruff, Kristine Harris,Huston, Kevin,Ross, Philip C.
, p. 69 - 80 (2007/10/03)
A series of 3-aminomethylbiphenyls were prepared in three steps from 3-phenylbenzoic acid and their affinities for the D2, D3 and D4 dopamine receptor subtypes determined. Most of the compounds described contained unique amine subunits of known dopaminergic agents. The compounds containing the amino tails present in the antipsychotic drugs haloperidol, pimozide and miliperidine displayed selectivity for the D2 receptor. Five-fold selectivity for the D4 receptor was observed in the compound 1-(3-biphenyl)-4-(2-pyrimidyl)piperazine. This selectivity for D4 vs. D2 receptors is comparable to that observed with the atypical antipsychotic clozapine.